GHK-Cu (glycyl-l-histidyl-l-lysine copper complex) is a tripeptide-copper complex with a long history in dermal cosmetic formulations and a much shorter one in regulated medicine. It binds copper ions in a way that affects collagen synthesis, antioxidant enzyme activity, and skin remodeling — at least in vitro.
The regulatory and clinical picture has tightened in 2025 and 2026. The PCAC has heard public comment on GHK-Cu's place on the 503A bulks list. State medical boards have moved against clinics injecting it as a research peptide. The cosmetic-peptide market continues to use it freely in topical products under various naming conventions.
Stories here cover regulatory action, dermatology research, and the gap between cosmetic-grade evidence and clinical-grade evidence. See #copper-peptide, #cosmetic-peptide, and #skincare for adjacent threads.
The FDA confirmed the Pharmacy Compounding Advisory Committee will convene a second meeting before the end of February 2027 to review five additional peptides for potential 503A Bulk Drug Substances List inclusion: GHK-Cu (injectable formulation specifically — topical/cosmetic remains separate), Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Mechano Growth Factor Pegylated (PEG-MGF). The February 2027 meeting follows the July 23-24, 2026 PCAC that will review seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2). Compounding pharmacies cannot legally compound these five peptides until the PCAC review concludes and the FDA issues a final determination — a 6-12 month timeline post-meeting. The peptide-specific indications under review span aesthetic dermatology (GHK-Cu, Melanotan II), antimicrobial activity (LL-37), neuroprotection (Dihexa), and growth-factor-mediated tissue regeneration (PEG-MGF).
A May 12 GlobeNewswire industry report frames the consumer peptide wellness market as approaching $300B globally on accelerating mainstream demand for science-backed peptide products spanning energy, recovery, metabolism, healthy aging, fitness, and overall well-being. The report tracks the post-Category-2 commercial cycle for BPC-157, TB-500, GHK-Cu, sermorelin, and the broader peptide supplement and cosmeceutical landscape — including OMI Wellbeauty's hair-growth peptides, Neurogan's 2% GHK-Cu body care, Auro Wellness's copper tripeptide serum, and the early-stage longevity peptide programs at Hims & Hers and LifeMD. The framing arrives six weeks ahead of the FDA's PCAC July 23-24 meeting that will decide compounding-pharmacy status for seven additional peptides including Emideltide (DSIP), Semax, and Epitalon.
A 2026 Frontiers in Aging review consolidates the case for therapeutic peptides as gerontology agents, mapping mechanisms across mitochondrial-derived peptides (MOTS-c, humanin), thymic peptides (thymosin alpha-1), wound-and-tissue-repair peptides (BPC-157, TB-500), copper peptides (GHK-Cu), and growth-hormone secretagogues (CJC-1295, ipamorelin). The review frames the longevity peptide field as a clinical category that now sits alongside GLP-1 metabolic medicine — driven by Hims & Hers' 2026 longevity-specialty launch, Drexel's May 5 Q&A on peptide popularity, and the FDA Category 2 removal of 12 peptides on April 22. The piece also flags that BPC-157, TB-500, and most wellness peptides still lack published human RCTs, with clinical use largely based on case reports and preclinical mechanistic rationale.
Neurogan Health expanded its product line with a topical 2% GHK-Cu copper peptide body care, supported by a 12-week clinical trial reporting 32.8% reduction in wrinkle depth and 20–30% improvement in skin firmness. The launch lands in a 2026 GHK-Cu market characterized by surging consumer interest — the peptide is the fastest-growing skincare ingredient by search volume, with patient interest spanning skin rejuvenation, hair loss, and systemic longevity. Topical GHK-Cu has the strongest evidence base among research peptides, going back decades on wound healing and collagen synthesis, and topical applications avoid the regulatory gray zone around the injectable formulation.
Scientific American published a comprehensive April 18 feature examining the self-injection wellness peptide movement, focusing on BPC-157, TB-500, GHK-Cu, KPV, and ipamorelin. The piece notes that only three small pilot studies have looked at BPC-157 in humans, that most evidence is from rodent models, and that consumers are ordering the compounds from overseas — usually from China — while the FDA prepares to review the category at its July advisory panel.
PharmaTher Holdings filed a U.S. provisional patent on April 13 for stabilized peptide compositions delivered via its PharmaPatch microneedle platform, covering formulations for BPC-157, GHK-Cu, TB-500, KPV, and multi-peptide combinations. The April 16 announcement positions PharmaTher to capture needle-free delivery share if the FDA's July PCAC meeting moves peptides back to Category 1. Three of the four compounds are on the July agenda.
Wellness platform Noom acquired Tailor Made Compounding (TMC), a licensed 503A pharmacy operating in 46 states, marking its largest investment in healthy aging. Noom plans to expand its formulary to include peptide therapies like sermorelin and GHK-Cu alongside NAD+ and hormone treatments.
Pharmaceutical platform BoomRx debuted its copper peptide skincare line at the A4M Longevity SpringFest conference in West Palm Beach. The flagship product features Copper Tripeptide-1 (GHK-Cu), targeting med-spa and wellness practices already offering GLP-1, hormone, and hair loss treatments.
Researchers from UNSW examine the booming trend of injectable peptides marketed for skin repair and anti-aging. They highlight the lack of human clinical evidence and note three people were fined for peptide injections that hospitalized two women at an anti-aging festival.
Combining multiple peptides like GHK-Cu, BPC-157, and TB-500 is becoming a growing trend, especially among GLP-1 medication users dealing with skin laxity from rapid weight loss. Goop feature explores risks and benefits with dermatologist input.
Noom acquired Tailor Made Compounding, a licensed 503A pharmacy in 46 states serving 400+ clinics, offering compounded peptides including sermorelin, GHK-Cu, and oxytocin.
Dermatology Times Q&A explores advances in GHK-Cu delivery for skincare, discussing how the peptide complexes with copper in human plasma and new formulation approaches to improve topical efficacy.